StockIQ.techBecton Dickinson and Company (BDX) Stock Analysis
Free AI-powered analysis and research for Becton Dickinson and Company stock
Sector: Healthcare
BDX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Becton Dickinson and Company scores 60/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 96% of its 52-week range, up 41.9% over the past year. Latest reported figures show a profit margin of 4.2%, return on equity of 6.6% and revenue growth of +5.4%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (46.0): -10
- Weak Profit Margin (4.2%): -8
- Low Liquidity (0.86 Current Ratio): -10
- Strong Long-term Uptrend: +8
- Strong Momentum (+41.9% over 1 year): +8
- Low Volume (0.4x): -3
- Near 52-Week High (96%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BDX report
Becton Dickinson and Company (BDX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BDX Now →📰 Latest Update
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Tue, November 3, 2026 at 1:15 PM UTC 4 min read
Becton Dickinson (BDX) is expected to report Q4 earnings of $4.06 per share, reflecting a 2.5% year-over-year increase, while revenues are projected to decline by 13% to $5.12 billion. Analysts have not revised their consensus EPS estimate in the past month, indicating stability in forecasts. With a Zacks Rank #2 (Buy), BDX shares have risen 9.9% over the last month, suggesting potential outperformance compared to the broader market.